Meningococcal (Meningitis) Vaccine Booster Recommendation
The Center for Disease Control (CDC) has a new recommendation in regard to the meningitis vaccine. This recommendation now includes a booster. The recommendation for routine vaccination of persons with quadrivalent meningococcal conjugate vaccine at age 11 or 12 years, with a booster dose at age 16 years. For adolescents who receive the first dose at age 13 through 15 years, a one-time booster dose should be administered, preferably at age 16 through 18 years, before the peak in increased risk. Persons who receive their first dose of meningococcal conjugate vaccine at or after age 16 years do not need a booster dose.
For additional information on this recommendation follow the CDC link Updated Recommendations for use of Meningoccocal Conjugate Vaccines
For additional information about the Meningococcal vaccine follow the CDC link Meningococcal Vaccine.
Human Papilloma Virus (HPV) Vaccine Now Recommended for use in Males
The Food and Drug Administration (FDA) licensed quadrivalent human papillomavirus vaccine (HPV4; Gardasil, Merck & Co. Inc.) and the CDC recommends it for use in males aged 9 through 26 years for prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11. The 3-dose series of HPV4 may be given to males aged 9 through 26 years to reduce their likelihood of acquiring genital warts.
Two HPV vaccines, Cervarix and Gardasil, are are licensed, safe, and effective for females ages 9 through 26 years. The CDC recommends that all girls who are 11 or 12 years old get the 3 doses (shots) of either brand of HPV vaccine to protect against cervical cancer. Gardasil also protects against most genital warts, as well as some cancers of the vulva, vagina, and anus. Girls and young women ages 13 through 26 should get all 3 doses of an HPV vaccine if they have not received all doses yet.
Gardasil is also licensed, safe, and effective for males ages 9 through 26 years. Boys and young men may choose to get this vaccine to prevent genital warts, and anal cancer.
For additional information on this recommendation follow the CDC link FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males.
For additional information about the HPV vaccine follow the CDC link HPV Vaccine.
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Updated Recommendation
The CDC recommends a single Tdap dose for persons aged 11 through 18 years who have completed the recommended childhood diphtheria and tetanus toxoids and pertussis/diphtheria and tetanus toxoids and acellular pertussis (DTP/DTaP) vaccination series and for adults aged 19 through 64 years. On October 27, 2010, ACIP approved the following additional recommendations:
use of Tdap regardless of interval since the last tetanus- or diphtheria-toxoid containing vaccine,
use of Tdap in certain adults aged 65 years and older, and
use of Tdap in under vaccinated children aged 7 through 10 years.
The Advisory Committee on Immunization Practices (ACIP) recommends that pertussis vaccination, when indicated, should not be delayed and that Tdap should be administered regardless of interval since the last tetanus or diphtheria toxoid-containing vaccine. ACIP concluded that while longer intervals between Td and Tdap vaccination could decrease the occurrence of local reactions, the benefits of protection against pertussis outweigh the potential risk for adverse events.
For additional information on this recommendation follow the CDC link Tdap Updated Recommendation
For additional information about the Tdap vaccine follow the CDC link Tdap.
If you have any questions, need a booster shot, or are interested in receiving any of the above vaccines contact the Gonzaga Student Health Center at (509) 313-4066.
Phone: (509) 313-4052 or
Please leave a message
Fax: (509) 313-5516
704 East Sharp
(Corner of Sharp & Dakota)
Hours vary by semester & breaks - click here for schedule